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Abstract
BACKGROUND & AIMS—We performed a genome-wide association study (GWAS) to identify 
genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously 
reported genetic risk factors.
METHODS—We performed a GWAS of 862 persons with DILI and 10588 population-matched 
controls. The first set of cases was recruited prior to May 2009 in Europe (n=137) or the USA 
(n=274). The second set of cases were identified from May 2009 through May 2013 from 
international collaborative studies performed in Europe, the USA and South America. For the 
GWAS, we included only cases of European ancestry associated with a particular drug (but not 
flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze 
human leukocyte antigen (HLA) genes and single nucleotide polymorphisms (SNPs). After the 
discovery analysis was concluded, we validated our findings using data from 283 European 
patients with diagnosis of DILI associated with various drugs.
RESULTS—We associated DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; 
odds ratio [OR], 2.7; 95% CI, 1.9–3.8; P=2.4×10−8) and with rs72631567 on chromosome 2 (OR, 
2.0; 95% CI, 1.6–2.5; P=9.7×10−9). The association with A*33:01 was mediated by large effects 
for terbinafine-, fenofibrate-, and ticlopidine-related DILI. The variant on chromosome 2 was 
associated with DILI from a variety of drugs. Further phenotypic analysis indicated that the 
association between DILI and A*33:01 was significant, genome wide, for cholestatic and mixed 
DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 associated with 
cholestatic and mixed DILI as well as hepatocellular DILI. We identified an association between 
rs28521457 (within the LRBA gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6–2.7; 
P=4.8×10−9). We did not associate any specific drug classes with genetic polymorphisms, except 
for statin-associated DILI, which was associated with rs116561224 on chromosome 18 (OR=5.4; 
95% CI, 3.0–9.5; P=7.1×10−9). We validated the association between A*33:01 terbinafine- and 
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sertraline-induced DILI. We could not validate the association between DILI and rs72631567, 
rs28521457, or rs116561224.
CONCLUSIONS—In a GWAS of persons of European descent with DILI, we associated HLA-
A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. We identified 
polymorphisms that appear to be associated with DILI from statins, as well as 2 non–drug-specific 
risk factors.
Keywords
medication; liver damage; side effect; anti-fungal agent
Introduction
Hepatotoxicity is the second most common cause of drug attrition during development as 
well as for post-marketing withdrawal,1 and idiosyncratic drug-induced liver injury (DILI) 
accounts for 11%-17% of cases of acute liver failure in the United States and Europe.2, 3 The 
typical incidence of DILI varies from approximately 1% with the anti-tumor necrosis factor 
agents4 to 0.04% with some widely used antimicrobials such as amoxicillin-clavulanate.5 
During the past 15 years, increasing progress on identifying genetic risk factors for DILI has 
been made. In particular, associations with HLA class I and II alleles have been reported for 
DILI caused by a range of drugs, though a particular HLA genotype does not appear to be 
relevant to all forms of idiosyncratic DILI.6
Previously, GWAS involving cohorts of DILI cases related to one particular drug only have 
resulted in identification of one or more drug-specific HLA risk alleles.7-11 A large study 
involving 783 DILI cases due to a range of different drugs also resulted in a genome-wide 
significant HLA signal, but this association was abolished once 296 cases of DILI due to 
flucloxacillin and amoxicillin-clavulanate were excluded.12 This partly reflects the fact that 
amoxicillin-clavulanate is a very common cause of DILI worldwide and flucloxacillin is an 
equally common cause in a number of Northern European countries.13 Therefore, DNA 
collections from DILI cases generally will be highly enriched in cases relating to these two 
drugs, making detection of associations related to other compounds more difficult.
We have expanded our previous study of DILI caused by a range of different drugs,12 and 
after excluding cases relating to amoxicillin-clavulanate and flucloxacillin, we have more 
than doubled the number of cases with additions from Europe, Australia, South America and 
the United States. We now report that HLA-A*33:01 is associated with risk of DILI, 
particularly due to terbinafine, fenofibrate and ticlopidine and especially with a cholestatic 
or mixed phenotype. We have also found novel non-major histocompatibility complex 
(MHC) related signals apparently shared across a range of different drugs; an intronic SNP, 
in the LPS-responsive vesicle trafficking, beach and anchor containing (LRBA) gene is 
associated with hepatocellular DILI and an intergenic SNP on chromosome 2, rs72631567, 
with DILI generally. An additional drug-specific genome-wide significant signal which 
could not be confirmed is also reported.
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Materials and Methods
DILI discovery cohort
The cases in the study were from two separate recruitment phases. Phase I consists of 411 
cases included in a previous study (from DILIN, DILIGEN and Eudragene)12 and phase II 
more recently recruited cases (n=451) of which a small subset was included in a recent 
report.14
Phase I cases—These cases included 413 DILI cases not due to amoxicillin-clavulanate 
or flucloxacillin, with a defined casual drug and with causality score greater than possible 
(RUCAM score≥3) recruited in Europe (n=137) or the USA (n=274) prior to 2009. Clinical 
characteristics of these cases and methods used for genotyping have been described in detail 
previously.12 Additional exome chip analysis (Illumina Infinium HumanCoreExome 
BeadChip) was performed on 150 of these 413 cases at the Broad Institute, Boston.
Phase II case recruitment-iDILIC—The iDILIC cases were recruited between May 
2009 and May 2013 as part of an international collaborative study involving recruitment 
centers in the United Kingdom (Newcastle, Nottingham, Liverpool, London, Dundee), 
Sweden (Uppsala and Gothenburg), Spain (Malaga and Barcelona), France (Montpellier), 
the Netherlands (Utrecht), Germany (Kiel), Australia (Brisbane), Switzerland (Zurich), 
Finland (Helsinki), Argentina (Rosario), Uruguay (Montevideo) and Chile (Santiago). All 
participants provided written informed consent and each study had been approved by the 
appropriate national or institutional ethical review boards. For the GWAS, only cases of 
European ancestry where there were at least 2 cases due to a particular drug available (when 
phase I cases from Europe and the USA were also considered) and where the DILI was not 
due to either flucloxacillin or amoxicillin-clavulanate were included (n=339). Clinical 
inclusion criteria for all cases were those described by Aithal et al.15
Phase II case recruitment-DILIN—Details of the USA-based DILIN prospective study 
including IRB approval information have been described previously.16 A total of 112 
eligible new cases of European ancestry and ≥ 18 years were included in the current GWAS. 
These new cases were selected from the larger DILIN sample collection such that only cases 
relating to drugs also included among the iDILIC cases were represented. Laboratory 
inclusion criteria were as described previously.16 Patients were excluded if there was known 
or suspected acetaminophen overdose, if there was a history of bone marrow or liver 
transplant prior to DILI onset or if there was a prior history of immune-related liver disease 
such as autoimmune hepatitis.
Additional cases used for confirmation of associations
After the discovery analysis was concluded, we enrolled an additional 283 European patients 
with diagnosis of DILI across multiple causal drugs (6 from iDILIC and 277 from DILIN 
networks recruited subsequent to the GWAS). The causal drug distribution is reported in 
Table S1A. An additional 12 statin DILI samples from the Spanish iDILIC network and 3 
UK-DILIGEN cases were recruited later in the study to confirm the class specific 
association (Table S1B).
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Out of the 283, we used 272 DILI cases to directly type SNPs associated across multiple 
drugs or specific for drugs/drug classes and 11 DILI cases for HLA typing to confirm HLA 
associations. An additional Chinese terbinafine DILI sample was also HLA typed.
Causality assessment
The iDILIC cases were evaluated by application of the Council for International 
Organizations of Medical Science (CIOMS) scale, also called the Roussel Uclaf Causality 
Assessment Method (RUCAM)15 and by expert review by a panel of three hepatologists. 
The pattern of liver injury was classified according to the International Consensus Meeting 
Criteria.17 Only cases having at least possible causality (score ≥3) were included in the 
study. For all cases in DILIN, causality assessment was by expert consensus as previously 
described.16
Controls
Since DILI has a very low prevalence, we used general population samples as study controls. 
We selected 10588 European ancestry controls from multiple available sources; Welcome 
Trust Case Control Consortium (WTCCC) (http://www.wtccc.org.uk), the population 
reference sample (POPRES)18, PGX4000119 and Spanish Bladder cancer cohort 
(phs000346.v1) from dbGAP.20 In order to increase the case/control ratio for Italian, 
Spanish and Swedish, we added samples from Hypergenes cohort (http://
www.hypergenes.eu/dissemination.html#pub), the National Spanish DNA Bank (http://
www.bancoadn.org/), Italian Penicillin Tolerant Controls (IPTC), and the Swedish Twin 
Registry (http://ki.se/en/research/the-swedish-twin-registry).
Genotyping
DNA preparation from Phase II cases—For iDILIC cases, DNA was prepared as 
described previously.8 DILIN DNA was extracted from lymphocytes and stored at the 
NIDDK biosample repository at Rutgers University, Piscataway, NJ.
Genome-wide analysis—Genome-wide genotyping of the phase II and 150 phase I cases 
was performed by the Broad Institute, Boston by Illumina Infinium HumanCoreExome 
BeadChip. iDILIC and DILIN cases were genotyped in two separate batches. A total of 
505740 markers shared across the batches passed quality control (QC) and no samples were 
excluded for low quality profile. (see Supplemental Materials and Methods). Details on the 
genotype data available for each control collection are reported in Table S2.
Imputation—SNP imputation was performed in batches dividing the cohorts according to 
genotyping platforms. Imputation methods are described in detail in the Supplementary 
Appendix. For HLA genotypes, four digit HLA alleles were inferred using HIBAG.21
SNP genotyping—The top associated imputed SNPs were validated by SNP genotyping 
in subsets of iDILIC cases and in the overall DILIN cohort (see Supplementary Appendix). 
The SNPs were further confirmed in additional cases using TaqMan® predesigned and 
custom SNP genotyping assays (ThermoFisher Scientific, Waltham, MA) in accordance with 
the manufacturer's recommendations.
Nicoletti et al. Page 6
Gastroenterology. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HLA genotyping—High resolution genotyping of HLA-A, B, C, DRB1, DQA1 and 
DQB1 was performed on selected cases by Histogenetics (Ossining, New York). Sequencing 
data files were analyzed using Histogenetics’ proprietary analysis software (Histomatcher 
and HistoMagic) for HLA genotype calling. Allele assignments are based on IMGT/HLA 
Database release version 2.21.0, dated April 2008 (http://www.ebi.ac.uk/imgt/hla/).
Statistical analysis
The effect of population structure was assessed through principal components analysis 
(PCA) using the smartPCA program from the EIGENSTRAT package (version 3.0).22 
Single marker and haplotype association analyses and heterogeneity test analyses were 
carried out by PLINK.23 The statistical association of each marker, HLA alleles and SNPs, 
was determined in a logistic regression framework with scores for the first seven principal 
components as covariates under an additive model using PLINK. We used the same 
statistical test for sub-population analyses, using two, seven and ten most significant 
principal components as covariates in Italian, Spanish and North European populations, 
respectively. We set the genome-wide traditional significance p-value threshold to 5.0×10−8 
to correct for multiple testing.24 When we obtained genome-wide significant signals, we 
tested for independent effects from the neighboring variants by including the most 
associated variants as a covariate and then testing the significance of others in the region. We 
also tested interaction effects among them by including interaction terms in the logistic 
regression. Differences in clinical characteristics among sample groups were tested by 
Fisher's exact test. All detailed analyses and Manhattan plots were performed with R 
(Version 3.0.2).25 Regional plots were drawn by LocusZoom.26
Results
Clinical characteristics of the cases
Clinical details of the DILI cases included in the main GWAS are summarized in Table 1. A 
variety of different causative drugs were represented but the most common was diclofenac 
with 67 cases, followed by nitrofurantoin with 64 cases. A few drugs, including 
azathioprine, isoniazid, fenofibrate, and diclofenac had significantly disproportionate 
number of cases in one of the two recruitment phases. Details of all the causative drugs are 
shown in Table S3.
Overall analysis
The discovery cohort included 862 European ancestry DILI cases (411 from phase I12 and 
451 from Phase II) and 10,588 controls. PCA showed that all cases (including those from 
South America) clustered within three major groups (Italian, Spanish and Northern 
European) and matched with the population controls (Figure S1A). Consistent with the 
previous study,12 phase I cases were predominantly Northwest European. The most 
significant genome-wide associated SNPs were rs72631567 on chromosome 2 (OR=2.0, 
95% CI =1.6-2.5, p-value=9.7×10−9) and rs114577328 in the MHC region of chromosome 6 
(OR=2.7, 95% CI=1.9-3.8, p-value=2.4×10−8)(See Figure 1A, Table 2 and Figures S2 and 
S3). Data for both SNPs had been obtained by imputation in cases and controls and 
subsequently validated by SNP typing (see Supplementary Methods). The associations were 
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consistent among geographic clusters and study phases (Table S4) and not due to artefact/s 
of population structure, missing genotypes rate (Table S5) or variability in imputation 
quality among populations or genotyping platforms (see Supplementary Methods).
For the chromosome 2 SNP rs72631567, breakdown by drug showed that 10 unrelated drug 
causes had an OR greater than 2.0 with at least two carriers (Table S6). Ciprofloxacin-
related cases showed the strongest association (n=21, OR=7.4, 95% CI=17.3-161, p-value = 
4.0×10−6).
The chromosome 6 SNP rs114577328 is the SNP proxy of an uncommon HLA class I allele, 
HLA-A*33:01. Indeed this SNP was in near-perfect LD with A*33:01 (r2=0.98). From the 
imputed HLA allele assignments, a strong association with DILI for this allele is confirmed 
(OR=2.6; 95% CI=1.8-3.7, p-value=8.0×10−8, Figure S4). Including rs114577328 or 
A*33:01 as a covariate removed any association in the MHC region, indicating that there is 
only one MHC association signal (Figure S5). The A*33:01 association appears independent 
of the chromosome 2 signal, since rs72631567 when conditioned on A*33:01 showed an 
almost unchanged effect size (ORrs72631567 = 1.7, 95% CI= 1.25-2.2, p-value = 0.0006). 
There was no statistically significant interaction effect between the two signals (p-value = 
0.5).
Breakdown by drug showed DILI due to terbinafine was most strongly associated with the 
HLA-A*33:01 signal (OR=40.5, 95% CI=12.5-131.4, p-value=6.7×10−10) and a similarly 
strong association was seen with rs114577328 (OR=58.7, 95% CI=18.31-188.2, p-
value=7.3×10−12, Figure 1B and Figure S6). As summarized in Table 3, in addition to 
terbinafine cases, cases due to six additional drugs showed an association with A*33:01 with 
p-values lower than 0.01. The largest case subset related to terbinafine but we found that 
A*33:01 was also a risk factor for ticlopidine (OR=163.1, 95% CI=16.2-1642.0, p-
value=0.00002), methyldopa (OR=97.8, 95% CI=12.3-743.0, p-value=0.00001) and 
fenofibrate DILI (OR=58.7; 95% CI=12.3-279.8; p-value=3.2×10−7). Indeed, although fewer 
positive carriers were observed, A*33:01 also seems to be a common risk factor for enalapril 
(OR=34.8), sertraline (OR=29) and erythromycin DILI (OR=10.2). An erythromycin case 
was positive for A*33:03, an allele rare in European population controls (AF=0.002) which 
belongs to the A*33 group. Overall we found that 87% (n=36) of the A*33:01 positive 
carriers were also positive for HLA-B*14:02 and HLA-C*08:02. The haplotype showed a 
larger OR than A*33:01 as single marker in terbinafine (ORhaplotype =49.2, p-
value=9.54×10−11), ticlopidine (ORhaplotype =201; p-value= 7.2×10−6), fenofibrate 
(ORhaplotype 68.5; p-value=1.1×10−7) and erythromycin (ORhaplotype = 13.1; p-value=0.002) 
DILI but not with DILI as a phenotype (ORhaplotype =2.7; p-value= 1.6×10−7, Table S7).
We verified the imputed A*33:01 genotype by sequence-based HLA typing in 35 cases 
related to the main A*33:01-associated drugs (Table S8). The A*33:01 predictions were 
confirmed in all cases except that one methyldopa case was negative for this allele (false 
positive) and an additional terbinafine case was a carrier (false negative). This validation 
result suggests that methyldopa might not share the HLA risk factor. The validation 
confirmed that all the A*33:01-positive terbinafine cases carried the complete HLA 
A*33:01-B*14:02-C*08:02 haplotype, increasing the strength of the haplotype association 
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in the terbinafine DILI cases (ORhaplotype=70; p-value=8.7×10−13) and in the overall 
analyses (ORhaplotype=2.8; p-value=5.1×10−8). We also typed the A*33:01 proxy SNP across 
DILIN cases to confirm imputed genotypes. We found only one new carrier of the minor 
allele, not related to the major-A*33:01 associated drugs.
Analysis by type of injury and causative drugs
We further investigated the association of genotypes with particular patterns of DILI by 
grouping the cases into hepatocellular (HC) and cholestatic/mixed (CM) pattern. The 
chromosome 2 association described above was similar in the two phenotypic categories 
(direct comparison between CM cases vs HC cases, logistic p-value=0.5), although the 
effect was marginally stronger in the CM cases (Table 2). The association with rs114577328 
was genome-wide significant only in the CM cases (n=323, OR=5.3, 95% CI=3.4-8.2, p-
value=4.5×10−14, Figure 2B and Figure S6) and similarly with A*33:01 (OR=5.1; 95% 
CI=3.3-7.9, p-value=4.2×10−13, Figure 2B and Figure S6). Conditional analysis on the 
variant and HLA allele indicated only one genetic association was present in the region, as 
shown for the main analysis (Figure S7). There was no association between the proxy SNP 
or A*33:01 in the HC cases (n=474, OR for A*33:01=1.5, 95% CI=0.82-2.6, p-value=0.19, 
Table 2). The A*33:01-B*14:02-C*08:02 haplotype showed an ORhaplotype = 5.6; p-value = 
2.5×10−13 in CM cases.
The CM only terbinafine-specific OR increased two fold compared with the value for all 
terbinafine cases (OR=88.1, 95% CI = 19.3-402.4, p-value = 7.5×10−9) since all the 
A*33:01 carriers belonged to this injury type. Following the injury correlation pattern 
established for terbinafine, A*33:01 appeared to be a stronger risk factor for CM injury than 
for HC injury also for fenofibrate, ticlopidine, enalapril and erythromycin-related DILI. This 
was not the case for injury due to sertraline and methyldopa. These top seven drugs account 
for 51% (n=21) of all A*33:01 positive cases (Table S9). Sixteen other drugs account for the 
rest of the carriers showing slight enrichment in CM phenotypes, which showed a marginal 
association with A*33:01 (OR = 2.6, 95% CI = 1.4-4.9, p-value = 0.003, Table S9 and Table 
S10).
We detected a new HC-specific genome-wide significant signal on chromosome 4 (Figure 
2B). The signal lies within the LRBA (LPS-responsive vesicle trafficking, beach and anchor 
containing) gene with the imputed variant rs28521457, located in an intronic region, the 
most significant SNP (OR=2.1, 95% CI=1.6-2.7, p-value=4.8×10−9)(Table 2 and Figure 2B). 
The allele frequency for this SNP in the CM cases (0.04) was comparable to that in controls 
with no evidence of association with this phenotype. The risk allele was carried by more 
than 4% of the HC cases in cases due to a total of 45 drugs but in general, there were no 
drug-specific signals (Table S11).
We also investigated associations with particular causative drugs or specific therapeutic 
classes where a group including more than 40 samples was available. Detail on the groups 
studied is summarized in Table S12. Genome-wide significance was detected only for one 
group examined, the statins, with no significant signals for the other drug classes (Figure S8 
and Table S13). In the case of the statins, rs116561224, a common intergenic SNP on 
chromosome 18, was genome-wide significant (OR=5.4, 95% CI=3.0-9.5, p-
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value=7.1×10−9, Figure 2C and Figure S9) with the signal mainly driven by simvastatin 
(Table S14).
Confirmation of associations
The European cohort used to confirm the associations (n=283) had a wider range of causal 
drugs, mostly different from the discovery cohort (Table S1). Later in time, we had access to 
15 additional cases relating specifically to the statin cohort.
The A*33:01 association was further investigated in the additional cases by directly 
genotyping rs114577328 in 272 cases and by direct HLA typing on 11 additional samples 
who developed DILI due to drugs for which we had detected an enrichment in A*33:01 
alleles in the discovery cases. Overall, the rs114577328 carriers were enriched in cases from 
drugs previously associated with the allele (Table S15). Eight out of all 23 additional cases 
relating to drugs previously associated with A*33:01 were shown to carry this allele or the 
proxy SNP (allele frequency 0.17) compared with an expected population frequency of 0.01. 
We specifically confirmed the association of A*33:01/rs114577328 with terbinafine having 
a carrier frequency of 0.63 (5 out 8 terbinafine-related cases across both the injury types) 
and with sertraline at a carrier frequency of 0.75 (3 out 4 sertraline-related cases) (Table 
S15). Although fenofibrate had a high carriage rate for A*33:01 in the discovery cohort, 
none of the 7 additional cases carried this allele or the proxy SNP. Few additional cases were 
available for other A*33:01-related drugs to confirm the association.
Interestingly, a terbinafine DILI case from Finland was positive for A*33:05, a very rare 
allele in the general European population (AF = 0.0001, USA NMDP European Caucasian 
in http://www.allelefrequencies.net/, n=1,242,890) and Finnish27 populations. An additional 
terbinafine DILI case of Chinese origin was positive for A*33:03. In total, 10 of the 24 
additional cases (23 European cases and one single Chinese case) were carriers of an A*33 
allele, in line with expectations based on the effects observed in the discovery sample.
We further genotyped rs72631567 and rs28521457 in 272 additional European cases. The 
rs72631567 and rs28521457 variants were found at AFs comparable to those for controls 
(AFrs72631567 = 0.022 and AFrs28521457 in HC only = 0.025) and so the association was not 
confirmed. However, rs72631567 carriers were slightly enriched in ciprofloxacin, 
atorvastatin and mercaptopurine-induced DILI cases, as in the discovery cohort, with ORs in 
the same direction in both cohorts (Table S16). Similarly, rs28521457 carriers seemed to be 
more common in the same subgroup of causal drugs in both cohorts (Table S17). This 
suggested a limited replication of the signal for these drugs.
We also attempted to confirm the rs116561224 signal for statins. The number of additional 
cases available for this purpose was small (n=29, Table S1b) with only four simvastatin 
cases. None of the statin cases were positive for rs116561224 so the signal could not be 
confirmed.
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Discussion
Our previous studies have been successful in identifying genetic risk factors for both 
flucloxacillin and amoxicillin-clavulanate DILI.4, 6 However, our most recent GWAS did not 
identify any risk factors that were common for DILI in general or specific genetic risk 
factors for DILI due to individual drugs which accounted for a smaller number of cases of 
DILI.12 The current study included 451 additional cases of DILI due to a wide variety of 
causative drugs, including at least 10 DILI cases relating to each of 22 different drugs. This 
increase in numbers and the exclusion of the amoxicillin-clavulanate and flucloxacillin cases 
together with use of improved imputation methods has enabled the detection and 
confirmation of a novel genome-wide significant signal relating to a relatively rare HLA 
class I allele A*33:01. Though three other interesting signals were detected in the course of 
the study, an intergenic signal on chromosome 2, an intronic SNP in LRBA in HC cases only 
and a signal on chromosome 18 for statins, the failure to confirm these signals is a 
limitation. There are some indications that, as observed for HLA-A*33:01, the chromosome 
2 and LRBA signals are shared across multiple unrelated drugs instead of being non-drug-
specific risk variants. As supporting evidence, the chromosome 2 signal has been 
consistently associated in both replication and discovery cohorts with DILI due to 
ciprofloxacin, atorvastatin and mercaptopurine. There remains a possibility that replication 
could be achieved in a larger study involving a different mix of causative drugs but the 
degree of heterogeneity in drugs originally associated with the signals also increases the risk 
that these were chance observations.
Interestingly, unlike previously recognized HLA associations for DILI, A*33:01 also 
appears to be a risk factor for DILI due to several, structurally unrelated drugs. Our results 
also suggest that a haplotype comprising A*33:01, B*14:02, and C*08:02 may participate in 
concert to confer risk for DILI, as opposed to A*33:01 alone. However, because these alleles 
are so highly correlated, our current sample size does not allow us to distinguish between 
these possible explanations by genetic association evidence alone. This conceivable 
hypothesis could be further verified in a larger study, or by experiments with recombinant 
HLA proteins.28
In the case of terbinafine where the A*33:01 association showed genome-wide significance 
for cases relating to this drug only, information on the underlying mechanism for 
hepatotoxicity is limited, N-dealkylation leads to the formation of an aldehyde metabolite, 
TBF-A, and this metabolite shows reactivity with glutathione.29 It has been proposed that 
the GSH-adduct is transported across the canalicular membrane and concentrated in the bile 
where it may cause damage to biliary epithelial cells. There is limited data from the various 
case reports on an underlying inflammatory mechanism but it has been demonstrated that 
treatment of monocytes with terbinafine results in the release of the proinflammatory 
cytokines IL-8 and TNF-alpha.30 Metabolism of terbinafine is complex involving several 
different cytochromes P450.31 However, there was no evidence from the GWAS for a role 
for either CYP genes or innate immunity genes in the terbinafine DILI cases studied.
The other drugs showing the most convincing associations with A*33:01 were fenofibrate, 
ticlopidine and sertraline. Failure to see individual genome-wide significant associations 
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with these drugs is likely to be due to fewer cases being available than for terbinafine. The 
A*33:01 association was seen for 3 of 7 cases due to fenofibrate, all with CM DILI. The 
literature on fenofibrate DILI is quite limited, but it appears that this drug is extensively 
metabolized, mainly by CYP3A4,32 and there is a report of a drug interaction resulting in 
cholestatic injury33 together with other isolated reports of idiosyncratic cholestatic DILI.34
Ticlopidine-related DILI has been well studied previously, including two studies 
investigating genetic risk factors in Japanese individuals. Cholestatic liver injury also 
predominates in this form of DILI.35, 36 Ticlopidine is subject to extensive metabolism by 
several cytochrome P450 isoforms and carboxyesterase.37 A study in rats suggests that 
adducts are formed following metabolism by cytochrome P450 with evidence for toxicity 
after biliary excretion of glutathione-conjugated metabolites via MRP2-facilitated 
transport.38 In previous studies, 22 Japanese patients with ticlopidine DILI showed an 
association with an HLA haplotype including A*33:03 (odds ratio 13).39 In line with current 
observations, the association was strongest with cholestatic cases with 12 out of 14 cases 
positive for A*33:03. It should be noted that A*33:03 is relatively common in Japan with 
approximately 10 to 15% of individuals carrying this allele.
The observations on the HLA association for Japanese ticlopidine DILI cases were followed 
up by a report that those carrying a −2320T>C polymorphism in CYP2B6 were more 
susceptible to ticlopidine DILI due to high CYP2B6 expression (OR 2, p-value=0.04).40 The 
CYP2B6 polymorphism (rs7254579)41 is less frequent in Europeans than in Asians 
(MAFcau = 0.29, MAFasian = 0.45) and its low effect size limited our ability to replicate the 
association in this small European ticlopidine DILI population, but the non-significant effect 
is in the same direction as the previous study (OR=2.8, 95% CI=0.7-10.18, p-value=0.11).
In contrast with the three drug examples above, sertraline is associated predominantly with 
HC DILI.42-44 In line with this phenotypic association, there is evidence that sertraline can 
cause mitochondrial damage28 and induce endoplasmic reticulum stress45 in liver cells. 
There are parallels with a previous example of a HLA risk factor (DRB1*15:01) which is 
associated with predominantly CM DILI with amoxicillin-clavulanate but HC DILI with 
lumiracoxib.9, 10
In line with the Japanese report of a role for A*33:03 in ticlopidine DILI39 and a case report 
showing an association between A*33 and tiopronin-induced cholestasis in a Chinese 
patient,46 we found two DILI cases positive for A*33:03 after direct HLA typing. One of 
these was a Chinese terbinafine DILI case and the second a European-American with 
erythromycin DILI. In our imputed GWAS dataset, A*33:03 was carried by eight DILI cases 
due to a range of drugs in our cohort and showed an apparent risk effect for CM DILI but 
this was not genome-wide significant (OR=2.1, 95% CI=1.02-4.6, p-value=0.04). Another 
A*33 allele, A*33:05, was also represented in a terbinafine case from Finland. There is very 
strong homology between these three HLA-A*33 alleles at the protein sequence level with 
A*33:03 differing at only two positions from A*33:01 (Tyr instead of His at position 171 
and Lys instead of Arg at position 186) and A*33:05 differing at only one position (Arg at 
54 in place of Gln). In particular, all three alleles conserve the key residues for specific 
peptide binding within the B and F pockets.47 This is in contrast to a related HLA allele 
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A*31:01, which is associated with carbamazepine-induced skin rash,48 but does not appear 
to be a risk factor for DILI, where the B pocket sequence, though homologous, is not 
conserved.47
As mentioned above, the association of a common HLA allele with DILI due to chemically-
unrelated compounds had been observed previously for DRB1*15:0110 with amoxicillin-
clavulanate and lumiracoxib and for DRB1*07:0149 with DILI from lapatinib and 
ximelagatran. The association of A*33:01 with DILI in general and secondary to a number 
of structurally dissimilar compounds is consistent with these observations. Together with 
recent findings from in vitro studies on T-cell responses to flucloxacillin and amoxicillin-
clavulanate,50, 51 these observations support the hypothesis that either the parent drug or 
metabolites bind covalently to cellular or circulating proteins to form adducts in a 
mechanism that is probably slightly different to the direct drug effect seen with 
hypersensitivity reactions to abacavir.52 Adduct formation may then allow binding to the 
peptide binding groove of HLA molecules leading to activation and differentiation of T-cells 
with a consequent adaptive immune response-mediated liver injury. Evidence that the 
majority of the drugs showing the A*33:01 association undergo hepatic metabolism and 
biliary excretion may explain the stronger association of A*33:01 with CM DILI and could 
indicate that, unlike in the case of flucloxacillin and amoxicillin-clavulanate, metabolites 
contribute to the toxicity mechanism. Further investigation of potential interaction of both 
the various drugs and their metabolites with the A*33:01 gene product by molecular 
modelling and in vitro studies on T cells as previously undertaken for flucloxacillin50 would 
be of interest.
The novel association of HC DILI with LRBA is interesting because this gene is a 
biologically plausible DILI candidate. LRBA deficiency due to rare mutations is associated 
with primary immunodeficiency of variable severity with a particular feature of decreased 
regulatory T cell (Treg) levels, other immunodeficiencies and inherited autoimmune 
disease.53-56 Patients with mutations in LRBA leading to immunodeficiency have been 
demonstrated to show loss of cytotoxic T lymphocyte antigen-4 (CTLA4).57 Studies in a 
mouse model suggest that low CTLA4 is a risk factor for DILI.58 Unlike the HLA-A*33:01 
association, no genome-wide significant associations for single drugs were detected with the 
LRBA SNP and there were no obvious features in common between cases positive for the 
variant other than the HC phenotype. It remains possible that this association could be 
replicated if a larger cohort were available.
The intergenic signal on chromosome 2 is from a region 800 kb upstream from SOX11, is 
independent of A*33:01 and associated with an almost two-fold risk of DILI with the top 
SNP showing a frequency of 0.02 in Europeans. This risk factor seems to be shared across 
unrelated drugs among which ciprofloxacin showed the strongest association. The ENCODE 
project suggests there are no regulatory elements in this region so the basis for the signal is 
unclear. Neither rs72631567 nor any of its LD SNPs (r2>0.5) are known eQTL variants 
(http://www.gtexportal.org/). The failure to confirm this association and the absence of any 
apparent biological basis suggests the observed significance could have been a chance 
finding.
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Most data for individual drug classes that were comparatively well represented in our cohort 
were entirely negative but the finding of a signal for statins which was driven by several 
class members was entirely novel. Similar to the more general signal seen on chromosome 2, 
the chromosome 18 is intergenic with the closest known gene, cadherin 19 located approx. 
300000 bp downstream. Although functionally such a protein could be of relevance to the 
liver injury process,59 any biological significance seems tenuous. The failure to confirm the 
signal in additional cases could be due to the availability of only a small cohort of additional 
cases which reflects the rarity of this form of DILI.60
In conclusion, this study has detected a novel HLA association (HLA-A*33:01) in cases of 
DILI due to a number of different drugs, together with several novel non-HLA signals. 
Overall sensitivity and specificity of the A*33:01 allele as a predictor of DILI is low but our 
findings may be important for future drug treatment in cases of DILI due to one of the drugs 
for which the A*33:01 association is relevant. Follow-up studies are required to further 
explore the intergenic signal on chromosome 2, the biologically interesting signal in LRBA 
and the rs116561224 signal for statins in larger cohorts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Significant case enrollment, sample ascertainment and analytical/data coordinating support on the DILIGEN, 
Spanish DILI registry, Eudragene and iDILIC studies was provided by the International Serious Adverse Events 
Consortium (iSAEC). We are extremely grateful to Arthur Holden of iSAEC for his continuing support. We are 
grateful to Julia Patch and Julian Arbuckle for technical, study management and assistance with recruitment on the 
iDILIC study and to Daniele Cusi (Hypergenes), Patrik K. Magnusson (Swedish Twin Registry) and Javier Martin 
(Spanish DNA bank) for provision of control data. Contributors to sample collection via iDILIC, the Spanish DILI 
registry, EUDRAGENE, DILIN, DILIGEN and iSAEC are listed in the Appendix.
Funding
The genome-wide association study, HLA genotyping and iDILIC case enrollment and sample collection was 
funded by the International Serious Adverse Events Consortium with (Phase 2) membership support from Abbott, 
Amgen, Daiichi-Sankyo, GlaxoSmithKline,Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Takeda, and the 
Wellcome Trust. This is a summary of independent research partly (the DILIGEN and iDILIC sample collection) 
funded by the National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research 
Unit at the Nottingham University Hospitals NHS Trust and University of Nottingham. The views expressed are 
those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The DILIN 
(https://dilin.dcri.duke.edu/) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases 
of the National Institutes of Health (NIH) as a Cooperative Agreement (U01s) under grants: U01-DK065176 
(Duke), U01-DK065201 (UNC), U01-DK065184 (Michigan), U01-DK065211 (Indiana), U01DK065193 (UConn), 
U01-DK065238 (UCSF/CPMC), U01-DK083023 (UTSW), U01-DK083027 (TJH/UPenn), U01-DK082992 
(Mayo), U01-DK083020 (USC), U01-DK100928 (Icahn). Additional funding is provided by CTSA grants UL1 
RR025761 (Indiana), UL1 TR001111 (UNC), and UL1 UL1 RR024986 (UMich). The EUDRAGENE collaboration 
received support from the EC 5th Framework program (QLRI-CT-2002-02757). The Spanish DILI Registry is 
partly funded by the Spanish Medicine Agency, Fondo Europeo de Desarrollo Regional - FEDER (P10-CTS-6470, 
FIS PI12/00378). CIBERehd is funded by Instituto de Salud Carlos III. The Swedish case collection 
(SWEDEGENE) has received support from the Swedish Medical Products Agency, the Swedish Society of 
Medicine (2008-21619), Swedish Research Council (Medicine 521-2011-2440), and Swedish Heart and Lung 
Foundation (20120557). MM was supported by the National Institute for Health Research (NIHR) Biomedical 
Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. LI was supported by 
Instituto de Salud Carlos III (EC08/00250). MA was supported by CONICYT PIA/Basal PFB12.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the 
manuscript.
Nicoletti et al. Page 14
Gastroenterology. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Abbreviations
DILI drug-induced liver injury
GWAS genome wide association study
OR Odd Ratio
RUCAM Roussel Uclaf Causality Assessment Method
AF Allele Frequency
HC Hepatocellular
CM Cholestatic-Mixed
eQTL Expression quantitative trait loci
MHC Major Histocompatibility Complex
MAF Minor allele frequency
LD Linkage Disequilibrium
HLA Human leukocyte antigen
SNP Single Nucleotide Polymorphism
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Figure 1. 
Manhattan plots displaying the association results of (A) the overall analysis (n=864); (B) 
terbinafine only cases (n=14 cases). SNPs in green have a significance level less than 5×10−6 
and red have a significance level less than 5×10−8.
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Figure 2. 
Manhattan plot displaying the association results for (A) Cholestatic/Mixed only cases 
(n=323); (B) Hepatocellular only cases (n=474 cases); (C) Statin cases (n=59). SNPs in 
green have a significance level less than 5×10−6 and red have a significance level less than 
5×10−8.
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Table 1
Clinical details of the DILI cases included in the GWAS
CHARACTERISTICS Phase 1
(n=411)
Phase 2
(n=451)
Combined
(n=862)
Clinical information
Age (mean years) 51 54 53
% Female 63.0% 60.5% 61.8%
ALT (mean IU/L) 895.1 757.7 822.2
ALP (mean IU/L) 388.2 282.5 330.6
Latency (mean days) 201.7 177.4 188.2
Injury type
Cholestatic 76 87 163
Hepatocellular 202 272 474
Mixed 69 91 160
Not available* 64 1 65
Genotype chip
Illumina 1 M 261 261
Illumina 1M/Illumina Infinium HumanCoreExome
BeadChip
150 150
Illumina Infinium HumanCoreExome BeadChip 447 447
Illumina HumanOmniExpress BeadChip 4 4
Country of birth
USA 274 112 386
UK 71 79 150
Spain 16 95 111
Sweden 81 81
France 30 7 37
Germany 20 20
Italy 16 1 17
Others 4 56 60
*
Because of the retrospective nature of the phase I study, minimal clinical information needed to establish the type of injury were not available for a 
subset of initial NSAID DILI cases from DILIGEN because of missing ALP and upper limit of normal values.
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Table 2
Association effect size of rs72631567, A*33:01 and rs28521457 across different liver injury patterns
COHORTs Variant OR 95% CI P AFCases
AF
Controls
Entire
DILI cohort
rs72631567 2.0 1.6-2.5 9.7×10−9 0.05 0.03
A*33:01 2.6 1.8-3.7 7.0×10−8 0.02 0.01
rs28521457 1.5 1.3-1.9 5.1×10−5 0.06 0.04
Cholestatic
and Mixed
DILI cohort
rs72631567 2.4 1.7-3.4 9.5×10−7 0.06 0.03
A*33:01 5.0 3.3-7.9 4.2×10−13 0.04 0.01
rs28521457 1.0 0.7-1.5 0.9 0.04 0.04
Hepatocellular
DILI cohort
rs72631567 1.6 1.2-2.3 2.5×10−3 0.04 0.03
A*33:01 1.5 0.8-2.6 0.19 0.01 0.011
rs28521457 2.1 1.6-2.7 4.8×10−9 0.08 0.040
COHORTs = type of comparison; Variant = associated variant; OR=Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P=logistic p-
value; AF = allele frequency
Gastroenterology. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Nicoletti et al. Page 23
Table 3
Association effect size of A*33:01 signal for the causal drugs enriched in A*33:01 positive carriers
DRUGs
Number
of cases
tested
Number
of
A*33:01
alleles
in cases
OR 95% CI P CF
TICLOPIDINE 5 4 163.1 16.2-1642 0.00002 0.8
METHYLDOPA 4 2 97.8 12.8-743.8 0.00001 0.5
FENOFIBRATE 7 4 58.7 12.3-279.8 3.2*10
−7 0.43
TERBINAFINE 14 6 40.5 12.5-131.4 6.7*10
−10 0.43
ENALAPRIL 4 2 34.8 3.9-302.9 0.001 0.5
SERTRALINE 5 2 29 4-207.2 0.0008 0.4
ERYTHROMYCIN 10 2 10.2 2-51.7 0.005 0.2
DRUGs=Causal drug involved; OR=Odds Ratio; 95% CI = 95% Confidence Interval of the odds ratio; P=logistic p-value; CF= Carrier Frequency
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